Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**DA-8010 + paroxetine** is a combination of two orally administered small molecules. **DA-8010** is a novel selective muscarinic M3 receptor antagonist under development primarily for the treatment of overactive bladder, while **paroxetine** is a selective serotonin reuptake inhibitor (SSRI) widely approved and marketed for the treatment of major depressive disorder, various anxiety disorders, and other psychiatric and neurological conditions. Paroxetine acts by inhibiting the reuptake of serotonin into presynaptic neurons, thereby increasing synaptic serotonin activity. When used in combination, these drugs may be investigated for potential drug-drug interactions, pharmacodynamic or pharmacokinetic effects, or for specific therapeutic indications where both agents provide benefit, but compounding interactions and adverse effects must be carefully monitored.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DA-8010 + paroxetine.